Biotransplant Inc Watch

from 10-Q ~10 pages Material contract

from 10-K ~10 pages Material contract

from 10-Q ~50 pages Material contract

from 10-Q 1 page Material contract

from 10-Q 1 page Material contract

from 10-Q 1 page Material contract

from 10-Q 1 page Material contract

from 10-Q 1 page [Biotransplant Logo]

from 10-Q 1 page Title: Controller Terms: This Offer Is Contingent on Your Starting on or About December 9, 1991. Compensation: $65,000 Per Year/Six Month Review, No Guarantee of Salary Increase. Bonus: Eligible; With a Guaranteed Minimum of $5,000 for 1992. Equity: 10,000 Options; Subject to Approval by the Board of Directors. Agreements: Your Employment Is Subject to Your Signing a Confidentiality, Invention Agreement and a Non-Compete Agreement With Biotransplant and Review of Any Agreement You May Have With Others to Insure That Your Employment With Biotransplant Is Not in Conflict With Any Such Agreements. if These Terms Are Acceptable, Please Sign and Return One Copy of This Agreement. We Look Forward to Your Joining the Company and Sharing in Our New Challenge. Best Regards, /S/ Elliot Lebowitz Elliot Lebowitz, PH.D. President and C.E.O Agreed To: By: /S/ Richard V. Capasso Date: 11/14/91 Richard V. Capasso [Biotransplant Logo]

from 10-Q 1 page Title: Director of the Monoclonal Antibody Department Reporting to the Vice President of Research and Development Terms: This Offer Is Contingent on Your Starting on or Before September 9, 1991. Compensation: $70,000 Per Year Equity: To Be Determined by the Board of Directors Agreements: Your Employment Is Subject to Your Signing a Confidentiality, Invention Agreement and a Non-Compete Agreement With Biotransplant and Review of Any Agreement You May Have With Others to Insure That Your Employment With Biotransplant Is Not in Conflict With Any Such Agreements. if These Terms Are Acceptable, Please Sign and Return One Copy of This Agreement. We Look Forward to Your Joining the Company and Sharing in Our New Challenge. Best Regards, /S/ Bernice Schacter, PH.D. Bernice Schacter, PH.D. Vice President Research & Development Agreed To: By: /S/ Mary White-Scharf, PH.D. Date: 8/7/91 Mary White-Scharf, PH.D. [Biotransplant Logo]

from 10-Q 1 page 1. Title: President and Chief Executive Officer Biotransplant, Inc. Reporting to the Board. 2. Term of Offer: This Offer Is Contingent on Your Starting Employment No Later Than May 1, 1991. 3. Compensation: $155,000 Per Year. Annual Bonus of Up to 30% of Salary, Payable on December 31 in Accordance With Goals Set by the Board. 4. Benefits: Health Benefits as Provided by the Company. 5. Equity: Common Stock Granted at $0.01 Per Share Equal to 5.0% of the Founding Capitalization of the Company Vested Over 4 Years Beginning With the First Anniversary of Employment. Stock Is Subject to Repurchase at Cost if Terminated for Cause. Eligible for Consideration for Future Stock Options at the End of Each Year Subject to the Discretion of the Board. 6. Severance: In the Event of an Involuntary Separation From Biotransplant, You Would Receive 6 Months Base Salary, Payable in 6 Equal Installments. 7. Confidentiality: A Standard Confidentiality Agreement Will Be Executed. if These Terms Are Acceptable, Please Sign and Return One Copy of This Agreement. We Are Delighted at the Prospect of Your Joining the Company. Best Regards. Sincerely, /S/ Harold R. Werner Harold R. Werner Director Biotransplant, Inc. Hrw:dv Agreed To: By: /S/ Elliot Lebowitz Date: April 7, 1991 Dr. Elliot Liebowitz

from 10-Q ~10 pages Assumed Eligix, Inc. 1997 Equity Incentive Plan Adopted June 30, 1997 as Amended August 31, 1998 as Amended January 28, 1999 Assumed by Biotransplant Incorporated on May 15, 2001

from 10-Q ~5 pages Assumed Eligix, Inc Amended and Restated Management Equity Incentive Plan

from 10-Q ~20 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. License, Assignment and Supply Agreement

from 10-Q ~5 pages Confidential Materials Omitted and Filed Separately With the Securities and Exchange Commission. Asterisks Denote Omissions. Agreement

from 10-Q ~10 pages Cummings Properties Management, Inc. Standard Form Commercial Lease

from 10-Q ~5 pages Material contract

from S-4/A ~20 pages Material contract

from 10-K 1 page Material contract

from S-4/A ~5 pages Material contract